Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Curvebeam AI (ASX:CVB): Could this company be the next Pro Medicus?

Not many ASX medtech companies can boast of a then US President elect as a patient, but Curvebeam AI (ASX:CVB) is one of them. And there's good reason too - because its technology can detect injuries and fracture risk where its peers cannot. CurveBeam AI and the secret sauce behind its technology CurveBeam AI develops and…

ByNick SundichAugust 13, 2024

Here’s why investors fear a US recession, and whether the fears are justified

Investors fear a US recession - there's no denying it and there's no other explanation for the market correction in the last week. But are these fears justified? Why investors fear a US recession Because there are data points that are showing markets could be headed that way. There was a very fine tightrope central banks…

ByNick SundichAugust 6, 2024

These ASX biotechs are working with the US Department of Defence to bring new drugs to market and have a bright future ahead

Think of ASX stocks working with the US Department of Defence, and investors might imagine defence stocks or perhaps even critical mineral project developers. This is not completely untrue. The list of stocks working with the US Department of Defence includes critical mineral companies such as Lynas (ASX:LYC), which was granted US$258m back in March 2024…

ByNick SundichJuly 30, 2024

Here’s why drug reimbursement is so important for ASX healthcare stocks

Let's take a look at the concept of drug reimbursement, something that is crucial for ASX healthcare stocks looking to sell their drugs or devices, especially in the USA. So the next time you see an announcement that an ASX-listed company has had their drug or device approved for reimbursement, you should wonder why a…

ByNick SundichJuly 25, 2024

Here’s how government funding for biotechs is immensely helpful for companies and their investors

Government funding for biotechs boosts the entire sector and the players in it - including ASX-listed companies. Many investors in listed biotechs may only see capital raisings as meaningful sources of funding. Even though the money allows for companies' endeavours to become possible, capital raisings have the negative connotation of diluting shareholders and may even…

ByNick SundichJuly 4, 2024

What are the best ASX Health Stocks for FY25? Here are our top 4 picks!

As FY24 has come to an end, we thought we'd list our best ASX Health Stocks for FY25! Traditionally, healthcare stocks are seen as defensive plays in dour markets. This has not proven to be the case in the last couple of years. Many ASX health stocks have suffered from high inflation and rising interest…

ByNick SundichJuly 1, 2024

How to minimise the risks of biotech shares on the ASX? Here are 4 traits investors should look for

To minimise the risks of biotech shares is a major challenge for investors, but not one that is insurmountable. The biotech sector on the ASX represents a substantial opportunity for investors to generate spectacular returns, while also having a major impact on the world around them. Investing in Biotech stocks takes patience Companies that have successfully…

ByNick SundichJune 14, 2024

Dimerix (ASX:DXB) just closed a 2nd licensing deal

Dimerix (ASX:DXB) did it again ASX-listed kidney disease drug developer Dimerix (ASX: DXB) is well positioned to bring its DMX-200 drug to market for Focal Segmental Glomerulosclerosis (FSGS). The drug is in a Phase 3 trial, which has shown solid interim results. The company secured its inaugural license deal in October 2023 with Advanz Pharma,…

ByMarc KennisMay 30, 2024

Recce Pharmaceuticals (ASX:RCE): Taking the fight against superbugs to the next level

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Sydney-based company fighting the battle against superbugs, with a legitimate chance of succeeding if the data to date is any guide. Bacterial infections have become an increasing problem as bacteria develop resistance to conventional antibiotics causing life threatening conditions such as sepsis. There is an urgent need for treatments…

ByNick SundichMay 20, 2024

Revascor’s FDA approval sends the Mesoblast rollercoaster upwards

Its been a rollercoaster ride for Mesoblast (ASX:MSB) shareholders, and although its been mostly downwards, the FDA approval of Revascor sent shares in the other direction. Is this a dead cat bounce, or a new beginning for the company? Long suffering shareholders would be scoff at the latter question, although there is no denying there…

ByUjjwal MaheshwariJanuary 24, 2024